Effectiveness of a third dose of BNT162b2 mRNA vaccine

Y Saciuk, J Kertes, N Shamir Stein… - The Journal of …, 2022 - academic.oup.com
A retrospective cohort study was carried out in a large Israeli health maintenance organization
to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against …

Association between AZD7442 (Tixagevimab-Cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

J Kertes, S Shapiro Ben David… - Clinical Infectious …, 2023 - academic.oup.com
Background Intramuscular AZD7442 (tixagevimab–cilgavimab [Evusheld; AstraZeneca])
has been found effective among immunocompromised individuals (ICIs) in reducing SARS-CoV-…

Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel

Y Saciuk, J Kertes, M Mandel, B Hemo, NS Stein… - Preventive …, 2022 - Elsevier
Abstract Development of an effective vaccine against Covid-19 is crucial to reducing infection.
mRNA BNT162b2, developed and manufactured by Pfizer-BioNTech, was one of the first …

[HTML][HTML] Effectiveness of mRNA BNT162b2 vaccine 6 months after vaccination among patients in large health maintenance organization, Israel

J Kertes, SB Gez, Y Saciuk… - Emerging infectious …, 2022 - ncbi.nlm.nih.gov
Israel experienced a new wave of coronavirus disease during June 2021, six months after
implementing a national vaccination campaign. We conducted 3 discrete analyses using data …

Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality

J Kertes, SSB David, N Engel-Zohar… - … diseases: an official …, 2022 - ncbi.nlm.nih.gov
Background Intramuscular AZD7442 (Tixagevimab–Cilgavimab,(Evusheld)) has been found
effective among immunocompromised individuals (ICI) in reducing Sars-Cov-2 infection …

[HTML][HTML] Post-acute sequelae of COVID-19 infection

K Jennifer, SBD Shirley, P Avi, RC Daniella… - Preventive medicine …, 2023 - Elsevier
To determine if people infected with SARS-CoV-2 were at higher risk of developing selected
medical conditions post-recovery, data were extracted from the database of a large health …

[HTML][HTML] Risk Stratification Model for Severe COVID-19 Disease: A Retrospective Cohort Study

M Mizrahi Reuveni, J Kertes, S Shapiro Ben David… - Biomedicines, 2023 - mdpi.com
Background: Risk stratification models have been developed to identify patients that are at a
higher risk of COVID-19 infection and severe illness. Objectives To develop and implement …

Comparison of perceptions and smoking cessation experiences between smokers with and without serious mental illness in a large health maintenance organization

J Kertes, Y Neumark, L Grunhaus… - Journal of Dual …, 2021 - Taylor & Francis
Objective Smoking prevalence is threefold higher among people with serious mental illness
(PWSMI) than in the general population, yet smoking cessation rates for PWSMI are lower. …

Comparison of Covid-19 antibody status after vaccination between residents in long-term geriatric care and residents assisted-living facilities

JE Naschitz, J Kertes, G Pinto, N Zaigraykin… - Infectious …, 2022 - Taylor & Francis
Objective To compare 2 CoV-SARS-2 (‘anti-s’) antibody levels after vaccination between
residents in long-term geriatric care (LTGC) and residents in assisted-living facilities who had …

[HTML][HTML] Use of a Virtual Multi-Disciplinary Clinic for the Treatment of Post-COVID-19 Patients

D Rahamim-Cohen, J Kertes, I Feldblum… - Healthcare, 2024 - mdpi.com
Post-COVID-19 has been recognized as possibly affecting millions of people worldwide. In
order to optimize care and ensure equality, we established a multidisciplinary virtual Post-…